Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Artiva priced its IPO at $12.00, raising $167 million. Artiva develops cell therapies for autoimmune diseases and cancer. AlloNK shows promise, targeting $1.7 billion in sales by 2038. Analysts initiated coverage, with Needham at $23 and Wedbush at $18. ARTV stock recently decreased by 0.36% to $11.18.
- Artiva priced its IPO at $12.00, raising $167 million.
- Artiva develops cell therapies for autoimmune diseases and cancer.
- AlloNK shows promise, targeting $1.7 billion in sales by 2038.
- Analysts initiated coverage, with Needham at $23 and Wedbush at $18.
- ARTV stock recently decreased by 0.36% to $11.18.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.